Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.
The anti-hypertensive therapeutics market is expected to grow significantly over the forecast period across the five Asia-Pacific (APAC) markets, from $19.1 Billion in 2015 to $27 Billion by 2022, at a compound annual growth rate (CAGR) of 5.1%. This growth is primarily attributed to the increasingly elderly population – where the prevalence rate of hypertension is at the highest – and increases in risk factors such as being overweight or obese, high daily sodium intake, low physical activity levels, urbanization, consumption of alcohol, smoking, and mental stress. In the five assessed APAC countries, the total population aged 65 and over was 1 Billion in 2015, and this is expected to grow at a CAGR of 3.32% to reach 1.2 Billion in 2022 (US Census Bureau, 2016).
The antihypertensive pipeline consists of 112 pipeline products, most of which are small molecules. Most of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 55%. Phase I, II and III products account for 40%, and Pre-registration products account for 4%.
In the five assessed APAC regions, the total estimated prevalence population of hypertension was approximately 548 million in 2015. Of these, approximately 335 million (61.1%) were undiagnosed. Moreover, among the diagnosed patients, approximately 104.7 million (49.1%) were untreated, while 108.5 million (50.9%) were treated with drug therapy. The low diagnosis and treatment rates are primarily due to the lack of awareness of the condition among healthcare professionals, patients, and the public. The asymptomatic nature of the disease is another major factor limiting the diagnosis rate, and a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China is another contributing factor.
Moreover, two major marketed products, Benicar/Olmetec (olmesartan medoxomil), and Rasilez (aliskiren), are expected to see their patents expire in Japan and Australia during the forecast period. The patent of Olmetec is expected to expire in Japan in 2016 and Australia in 2017, while the patent of Rasilez (aliskiren) is expected to expire in Australia in 2020. Increasing generic competition across the five APAC regions will restrict market growth during the forecast period.
The report “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline” provides an introduction to anti-hypertensive, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients.
In depth, it provides the following:
- Detailed analysis of the drugs currently marketed for anti-hypertensive (Cozaar, Benicar, Micardis, Diovan, Azilva, Norvasc, Rasilez, Tritace, Carvedilol, Prestalia, Exforge).
- Provides detailed analysis of the pipeline for anti-hypertensive, by stage of development, molecule type, program type, mechanism of action and molecular target.
- Detailed analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
Supplies forecasts for the anti-hypertensive markets, including epidemiology, treatment usage patterns, pricing and market size for the 2015–2022 period. The five APAC markets are covered, and data are presented at a country level.
- Detailed analysis of the key market drivers and barriers for the anti-hypertensive markets.
- Describes the major deals that have taken place in the global anti-hypertensive markets in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.